The Firm recently represented the underwriters, led by Barclays Capital Inc., Citigroup Global Markets Inc., and Merrill Lynch, Pierce, Fenner & Smith Incorporated, in connection with the public offering by Boston Scientific Corporation (“Boston Scientific”) of $1 billion of 4% senior notes due 2028. Boston Scientific will use the net proceeds to redeem outstanding senior notes and repay short term debt.
Boston Scientific, as a global medical technology leader for more than 35 years, advances science for life by providing a broad range of high performance solutions that address unmet patient needs and reduce the cost of healthcare.
The Simpson Thacher team for the transaction included Roxane Reardon and Davis Mahon (Capital Markets); Jonathan Cantor and Jodi Schneider (Tax); Noah Leibowitz, Marcela Robledo, Katherine Helm and Amber Harezlak (Intellectual Property); Michael Isby and Timothy Mulvihill (Environmental); Jeanne Annarumma and Alina Grinman (ECEB); and Jennie Getsin (FINRA/Blue Sky).